(Q38036917)

27 August 2017

MicroRNAs and drug resistance of breast cancer: basic evidence and clinical applications (English)

1 reference

27 August 2017

1 reference

1 reference

Wei Tian

1

1 reference

27 August 2017

Junqing Chen

series ordinal

2

1 reference

27 August 2017

Haifei He

series ordinal

3

1 reference

27 August 2017

Yongchuan Deng

series ordinal

4

1 reference

27 August 2017

23 August 2012

1 reference

Clinical and Translational Oncology

27 August 2017

1 reference

27 August 2017

15

1 reference

27 August 2017

5

1 reference

27 August 2017

335-342

1 reference

https://scigraph.springernature.com/pub.10.1007/s12094-012-0929-5

27 August 2017

0 references

cites work

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

MicroRNA regulation by RNA-binding proteins and its implications for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

MicroRNAs: target recognition and regulatory functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

Regulation of miR-19 to breast cancer chemoresistance through targeting PTEN

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

Recent advances in apoptosis, mitochondria and drug resistance in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

MicroRNA-21 modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

Targets of miR-200c mediate suppression of cell motility and anoikis resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actin-regulatory proteins FHOD1 and PPM1F.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

A novel network integrating a miRNA-203/SNAI1 feedback loop which regulates epithelial to mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

The epithelial-mesenchymal transition generates cells with properties of stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

Towards an integrated model for breast cancer etiology: the lifelong interplay of genes, lifestyle, and hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

Overview of the main outcomes in breast-cancer prevention trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

Exemestane for breast-cancer prevention in postmenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

Differential expression of microRNA expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

Biological determinants of endocrine resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

Mechanisms of endocrine resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

MicroRNA-101-mediated Akt activation and estrogen-independent growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

MicroRNA profiling: approaches and considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

Plasma miR-221 as a predictive biomarker for chemoresistance in breast cancer patients who previously received neoadjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0929-5

miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancer

21 January 2018

1 reference

12 December 2020

MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship

1 reference

12 December 2020

[Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR]

1 reference

12 December 2020

E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells

1 reference

12 December 2020

10.1007/S12094-012-0929-5

Identifiers

DOI

1 reference

27 August 2017

1 reference